Tumor immune microenvironment plays a crucial role in determining the effectiveness of PD-1 immunotherapy, with the expression level of PD-L1 in tumor cells and the density and phenotype of tumor-infiltrating T lymphocytes being important factors [23, 24]. Here, PDCD1 is linked to neoplasm.